Author: Customer Service

Revenue Grows 8% Year-Over-Year to $4.1 Million; Import and Metal Verticals Deliver Strong Double-Digit Growth NORTH WALES, PA, May 14, 2026 (GLOBE NEWSWIRE) — Toppoint Holdings Inc. (NYSE American: TOPP), a truckload services and solutions provider focused on the recycling export supply chain, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Highlights •  Revenue of $4.1 million, an increase of 8% compared to $3.8 million in Q1 2025 •  Import revenue surged 61.8% year-over-year to $1.4 million •  Metal vertical revenue grew 164.8% year-over-year to $565,647 •  Net cash used in operating activities improved by approximately $93,650 versus the prior-year quarter •  Total assets of $10.3 million as of March 31, 2026 •  Expanded geographic footprint into Houston, TX, and continued growth...

Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial  Company to provide detailed data update from Phase 2 CRDF-004 trial in rapid oral presentation at American Society of Clinical Oncology Annual Meeting Leadership additions position Company to execute on key upcoming clinical and regulatory milestones SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “This quarter was marked by the positive data update from our randomized Phase 2 CRDF-004 trial of onvansertib in first-line RAS-mutated metastatic...

ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million Fortress’ consolidated net income attributable to common stockholders for the first quarter of 2026 was $108.4 million, or $3.44 per common share (basic) and $2.82 per common share (diluted) MIAMI, May 14, 2026 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2026. Lindsay A. Rosenwald, M.D., Fortress’ Chairman,...

Record-lows in operating loss and non-GAAP operating loss since going public, achieving reductions of nearly 50% and 67.2% year-over-year, respectively. Generated quarterly gross margin of $4.3 million, expanding margins to 38.6% Delivered a Q1 record of 95 units, including 63 powertrains for Blue Bird school buses, more than 3 times the prior-year quarter LOS ANGELES, May 14, 2026 (GLOBE NEWSWIRE) — Xos, Inc. (NASDAQ: XOS) (“Xos” or the “Company”), a leading energy storage and fleet electrification solutions provider, today reported financial results for the first quarter ended March 31, 2026. Building on a year of disciplined execution and consistent operational improvement, Xos opened 2026 with its highest quarterly gross margin and lowest operating loss in Company history, reinforcing the durability...

Strong Execution Across All Pillars: First C&I Purchase Order, Georgia Manufacturing Facility on Track, and Multiple Strategic Milestones Validate Integrated Platform Strategy SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) — NeoVolta Inc. (NASDAQ: NEOV) (“NeoVolta” or the “Company”), a U.S.-based energy technology company delivering scalable energy storage solutions, today announced financial results for its third quarter fiscal 2026 ended March 31, 2026, and provided an update on the Company’s continued execution against its strategy to build a vertically integrated energy solutions platform serving residential, commercial and industrial (“C&I”), and utility-scale markets. Recent HighlightsNamed 2026 Energy Storage Company of the Year by CleanTech Breakthrough, selected from thousands of nominations across...

Revenue increased to $2.2 million, compared with $160,000 in the prior year period, driven by scaled deployment of Scrypt-based digital asset mining infrastructureSALT LAKE CITY, May 14, 2026 (GLOBE NEWSWIRE) — Datacentrex, Inc. (“Datacentrex” or the “Company”) (Nasdaq: DTCX), a diversified technology-driven enterprise operating a digital asset mining business, today reported financial results for the first quarter ended March 31, 2026. “Datacentrex’s Q1 2026 results reflect strong year-over-year growth, with mining operations generating $2.2 million of revenue compared to $160,000 from inception in Q1 2025,” said Parker Scott, Chief Executive Officer of Datacentrex. “Importantly, we generated $513,000 in gross profit, representing a 23.5% gross margin, despite a difficult mining environment in Q1 2026. While our reported net...

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) — Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2026 and provided an update on its business. During the second quarter, Edesa continued preparations for an upcoming Phase 2 clinical study of its drug candidate, EB06 (an anti-CXCL10 monoclonal antibody), in moderate-to-severe nonsegmental vitiligo patients. The company reported that it has contracted a clinical research organization and initiated outreach to potential clinical sites and investigators. Based on this progress, Edesa reaffirmed its previous guidance that site activations and patient recruitment are expected to begin midyear 2026, subject...

MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune disease, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three months ended March 31, 2026. The Company remains on track to provide preliminary clinical data readout from the first two dose levels of the Phase 1 clinical study evaluating HCW9302 in alopecia areata in the first half of 2026. There are two clinical sites actively enrolling patients, and enrollment has been on schedule. HCW9302 is an injectable, first-in-kind interleukin 2 (“IL-2”) fusion protein complex designed to suppress the hair-follicle killing activities...

Operating Performance Improves; Company Maintains Strategic Flexibility MINNETONKA, Minn., May 14, 2026 (GLOBE NEWSWIRE) — BT Brands, Inc. (Nasdaq: BTBD, BTBDW) (“BT Brands” or the “Company”) today reported financial results for the thirteen weeks ended March 29, 2026. BT Brands delivered improved operating performance during the first quarter of fiscal 2026, notwithstanding softness in restaurant sales and market volatility affecting its investment portfolio. The Company also announced that, following the termination of its merger agreement with Aero Velocity Inc., it continues to preserve strategic flexibility while evaluating opportunities to enhance shareholder value. First Quarter Fiscal 2026 HighlightsRestaurant operating performance continued to advance, driven by lower labor costs, leaner general and administrative expenses,...